Durata Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
November 15 2013 - 4:00PM
Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R.
Edick, CEO, will present an overview of the Company at the
Jefferies 2013 Global Healthcare Conference in London on Thursday,
November 21, 2013 at 1:00 PM (local UK time).
About Durata Therapeutics
Durata Therapeutics is a pharmaceutical company focused on the
development and commercialization of novel therapeutics for
patients with infectious diseases and acute illnesses. Durata has
completed two global Phase 3 clinical trials with its lead product
candidate, dalbavancin, under investigation for the treatment of
patients with acute bacterial skin and skin structure infections
caused by susceptible gram-positive bacteria.
Forward-looking statements
Any statements in this press release about Durata's future
expectations, plans and prospects constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, as amended. Actual results may differ
materially from those indicated by such forward-looking statements.
Durata anticipates that subsequent events and developments will
cause its views to change. However, while Durata may elect to
update these forward-looking statements at some point in the
future, Durata specifically disclaims any obligation to do so.
CONTACT: Allison Wey
Durata Therapeutics, Inc.
Vice President, Investor Relations and Public Affairs
(312) 219-7017
awey@duratatherapeutics.com
(MM) (NASDAQ:DRTX)
Historical Stock Chart
From Sep 2024 to Oct 2024
(MM) (NASDAQ:DRTX)
Historical Stock Chart
From Oct 2023 to Oct 2024